Combined beta- and Auger electron therapy using a novel somatostatin receptor subtype 2 antagonist labelled with terbium-161 (161Tb-DOTA-LM3) – a phase 0/ phase I study

New treatment modaliyt for PRRT in neuroendocrine tumors. Phase 0/1 study

Research Group Emanuel Christ